Prognosis and Novel Drug Targets for Key lncRNAs of Epigenetic Modification in Colorectal Cancer

Table 1

The clinical characteristics of the different sets.

Covariates	Type	Total set	Training set	Testing set	value
Age	≤65	227 (45.13%)	161 (45.35%)	66 (44.59%)	0.9543
	>65	276 (54.87%)	194 (54.65%)	82 (55.41%)
Gender	Female	225 (44.73%)	157 (44.23%)	68 (45.95%)	0.7985
	Male	278 (55.27%)	198 (55.77%)	80 (54.05%)
Race	Asian	9 (1.79%)	6 (1.69%)	3 (2.03%)	0.9398
	Black or African American	246 (48.91%)	175 (49.3%)	71 (47.97%)
	White	248 (49.3%)	174 (49.01%)	74 (50%)
Radiation	No	466 (92.64%)	329 (92.68%)	137 (92.57%)	1
	Yes	37 (7.36%)	26 (7.32%)	11 (7.43%)
Pharmaceutical therapy	No	301 (59.84%)	212 (59.72%)	89 (60.14%)	1
	Yes	202 (40.16%)	143 (40.28%)	59 (39.86%)
Pathological stage	Stage I	91 (18.09%)	61 (17.18%)	30 (20.27%)	0.7053
	Stage II	180 (35.79%)	129 (36.34%)	51 (34.46%)
	Stage III	155 (30.82%)	113 (31.83%)	42 (28.38%)
	Stage IV	77 (15.31%)	52 (14.65%)	25 (16.89%)
Stage T	T1	17 (3.38%)	12 (3.38%)	5 (3.38%)	0.0901
	T2	92 (18.29%)	60 (16.9%)	32 (21.62%)
	T3	343 (68.19%)	253 (71.27%)	90 (60.81%)
	T4	50 (9.94%)	30 (8.45%)	20 (13.51%)
	Tis	1 (0.2%)	0 (0%)	1 (0.68%)
Stage M	M0	377 (74.95%)	267 (75.21%)	110 (74.32%)	0.7588
	M1	77 (15.31%)	52 (14.65%)	25 (16.89%)
	Mx	49 (9.74%)	36 (10.14%)	13 (8.78%)
Stage N	N0	283 (56.26%)	200 (56.34%)	83 (56.08%)	0.7087
	N1	126 (25.05%)	86 (24.23%)	40 (27.03%)
	N2	92 (18.29%)	67 (18.87%)	25 (16.89%)
	Nx	2 (0.4%)	2 (0.56%)	0 (0%)
Status	Alive	403 (80.12%)	284 (80%)	119 (80.41%)	1
	Dead	100 (19.88%)	71 (20%)	29 (19.59%)

No: the patient have not receive the treatment; Tis: carcinoma in situ; Mx: unknown M stage; Nx: unknown N stage.